

Workshop - Nordic Meeting in Neuropsychology 2024

Title of workshop: "Indications for and expected effects of anti-amyloid treatments in Alzheimer's disease:

-A focus on cognitive aspects."

Presenters:

- Bjørn-Eivind Kirsebom, PhD, Associate professor, University Hospital of North-Norway/University of Tromsø, Norway
- Tormod Fladby, Professor at Institute for Clinical Medicine, University of Oslo/Akershus University Hospital, Oslo, Norway

Brief description of workshop:

For the first time, large clinical phase 3 trials have shown definite treatment effects on early Alzheimer's Disease (AD) progression. Effect sizes are from > 25% up to 46% compared to placebo, and vary depending on compound (Lecembi, Donanemab), and on patient inclusion criteria. Treatments are likely to be approved in the EU and Nordic countries late 2023 or 2024. Availability in the clinic is expected to be met with large demand, and a corresponding need for cognitive testing.

Trial results suggest larger effects at early AD stages, pointing to the need for early case identification. Thus, there is a need for a detailed understanding of incipient AD-related cognitive changes, and relation to non-AD (e.g. late-life depression-related, LLD) cognitive symptoms. Furthermore, a detailed understanding of clinical criteria for treatment is needed, as well as of expected treatment effects on cognitive aspects of disease progression.

The workshop will also cover key aspects of AD neuropathologies and diagnostic techniques (clinical, imaging, fluid biomarkers) as well as typical clinical manifestations and risks of side effects of treatments.

Learning-goals:

- Be familiar with cognitive criteria for anti-amyloid treatment in AD
- Understand the distinction between non-AD subjective and mild cognitive impairment, non-AD LLD and AD-related pre-dementia cognitive impairment.
- Understand expected treatment effects and possible side-effects as well as key neuropathological aspects of AD and treatments